Abstract
Objective
The cost of treatment as it affects comparative effectiveness is becoming increasingly more important. Because cost data are not readily available, we evaluated the charges associated with definitive nonsurgical therapy for early-stage lateralized tonsil cancers.
Methods
Patients treated with unilateral radiation therapy (RT) for T1 or T2 tonsil cancer between 1995 and 2007 were retrospectively reviewed. Total and radiation-specific charges, from 3 months before to 4 months after radiation, were adjusted for inflation. All facets of treatment were evaluated for significant associations with total billing.
Results
Eighty-four patients were identified. Three-year overall survival, disease-specific survival, and recurrence-free survival were 97 % [95 % confidence interval (CI) 0.88–0.99], 98 % (95 % CI 0.89–1), and 96 % (95 % CI 0.88–0.99), respectively. The median for radiation-specific charges was $60,412 (range $16,811–$84,792). The median for total charges associated with treatment was $109,917 (range $36,680–$231,895). Total billing for treatment was significantly associated with the year of diagnosis (p = 0.008), intensity-modulated radiation therapy versus wedge pair RT (p = 0.005), preradiation direct laryngoscopy (p < 0.0001), chemotherapy (p < 0.0001), gastrostomy tube placement (p = 0.004), and postradiation neck dissection (p = 0.005).
Conclusions
Although cost data for treatment are not readily available, historically, the recovery rate is approximately 30 %. The charges associated with definitive nonsurgical therapy for early-stage lateralized tonsil cancer have a wide range likely due to treatment-related procedures, the use of chemotherapy, and evolving RT technologies. These benchmark data are important given renewed interested in primary surgery for tonsil cancer. Cost of care, disease control, and functional outcomes will be critical for comparisons of effectiveness when selecting treatment modalities.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Keehan SP, Sisko AM, Truffer CJ, et al. National health spending projections through 2020: economic recovery and reform drive faster spending growth. Health Aff. 2011;30(8):1594–605.
Weber RS, Lewis CM, Eastman SD, et al. Quality and performance indicators in an academic department of head and neck surgery. Arch Otolaryngol Head Neck Surg. 2010;136(12):1212–8.
Weber RS. Improving the quality of head and neck cancer care. Arch Otolaryngol Head Neck Surg. 2007;133(12):1188–92.
Jacobson JJ, Epstein JB, Eichmiller FC, et al. The cost burden of oral, oral pharyngeal, and salivary gland cancers in three groups: commercial insurance, medicare, and medicaid. Head Neck Oncol. 2012;4(1):15.
Chronowski GM, Garden AS, Morrison WH, et al. Unilateral radiotherapy for the treatment of tonsil cancer. Int J Radiat Oncol Biol Phys. 2012;83(1):204–9.
Weinstein GS, Quon H, O’Malley BW Jr, Kim GG, Cohen MA. Selective neck dissection and deintensified postoperative radiation and chemotherapy for oropharyngeal cancer: a subset analysis of the University of Pennsylvania transoral robotic surgery trial. Laryngoscope. 2010;120(9):1749–55.
Tangka FK, Trogdon JG, Richardson LC, Howard D, Sabatino SA, Finkelstein EA. Cancer treatment cost in the United States: has the burden shifted over time? Cancer. 2010;116(14):3477–84.
Amonkar MM, Chastek B, Samant N, Teitelbaum A. Economic burden of resected squamous cell carcinoma of the head and neck in a US managed-care population. J Med Econ. 2011;14(4):421–32.
Epstein JD, Knight TK, Epstein JB, Bride MA, Nichol MB. Cost of care for early- and late-stage oral and pharyngeal cancer in the California Medicaid population. Head Neck. 2008;30(2):178–86.
Dedhia RC, Smith KJ, Weissfeld JL, et al. Cost-identification analysis of total laryngectomy: an itemized approach to hospital costs. Otolaryngol Head Neck Surg. 2011;144(2):220–4.
Funk GF, Hoffman HT, Karnell LH, et al. Cost-identification analysis in oral cavity cancer management. Otolaryngol Head Neck Surg. 1998;118(2):211–20.
Lang K, Sussman M, Friedman M, et al. Incidence and costs of treatment-related complications among patients with advanced squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 2009;135(6):582–8.
Nijdam W, Levendag P, Noever I, Uyl-de Groot C, van Agthoven M. Cost analysis comparing brachytherapy versus surgery for primary carcinoma of the tonsillar fossa and/or soft palate. Int J Radiat Oncol Biol Phys. 2004;59(2):488–94.
Moore EJ, Hinni ML, Olsen KD, Price DL, Laborde RR, Inman JC. Cost considerations in the treatment of oropharyngeal squamous cell carcinoma. Otolaryngol Head Neck Surg. 2012;146(6):946–51.
Tae K, Ji YB, Cho SH, Lee SH, Kim DS, Kim TW. Early surgical outcomes of robotic thyroidectomy by a gasless unilateral axillo-breast or axillary approach for papillary thyroid carcinoma: 2 years’ experience. Head Neck. 2012;34(5):617–25.
Ahmed K, Ibrahim A, Wang TT, et al. Assessing the cost effectiveness of robotics in urological surgery—a systematic review. BJU Int. 2012;110: 1544–56.
Acknowledgments
No grants supported this study.
Disclosure
Carol M. Lewis, Gregory M. Chronowski, Wenli Dong G. Brandon Gunn, David I. Rosenthal, and Randal S. Weber have no financial disclosures to make.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lewis, C.M., Chronowski, G.M., Dong, W. et al. Analysis of Charges Associated with Definitive Nonsurgical Therapy for Early-Stage Lateralized Tonsil Cancer. Ann Surg Oncol 22, 2755–2760 (2015). https://doi.org/10.1245/s10434-014-4298-x
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-014-4298-x